348 related articles for article (PubMed ID: 18362097)
21. Cognitive performance correlates with the degree of dopaminergic degeneration in the associative part of the striatum in non-demented Parkinson's patients.
Kübler D; Schroll H; Buchert R; Kühn AA
J Neural Transm (Vienna); 2017 Sep; 124(9):1073-1081. PubMed ID: 28643101
[TBL] [Abstract][Full Text] [Related]
22. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride.
Antonini A; Schwarz J; Oertel WH; Pogarell O; Leenders KL
Mov Disord; 1997 Jan; 12(1):33-8. PubMed ID: 8990051
[TBL] [Abstract][Full Text] [Related]
23. Neural correlates of standing imagery and execution in Parkinsonian patients: The relevance to striatal dopamine dysfunction.
Mori Y; Yoshikawa E; Futatsubashi M; Ouchi Y
PLoS One; 2020; 15(10):e0240998. PubMed ID: 33112886
[TBL] [Abstract][Full Text] [Related]
24. Impaired cognitive performance in Parkinson's disease is related to caudate dopaminergic hypofunction and hippocampal atrophy.
Jokinen P; Brück A; Aalto S; Forsback S; Parkkola R; Rinne JO
Parkinsonism Relat Disord; 2009 Feb; 15(2):88-93. PubMed ID: 18434233
[TBL] [Abstract][Full Text] [Related]
25. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study.
Pavese N; Evans AH; Tai YF; Hotton G; Brooks DJ; Lees AJ; Piccini P
Neurology; 2006 Nov; 67(9):1612-7. PubMed ID: 17101892
[TBL] [Abstract][Full Text] [Related]
26. [Cognition, schizophrenia and the effect of antipsychotics].
Stip E
Encephale; 2006; 32(3 Pt 1):341-50. PubMed ID: 16840928
[TBL] [Abstract][Full Text] [Related]
27. [
Stark AJ; Smith CT; Petersen KJ; Trujillo P; van Wouwe NC; Donahue MJ; Kessler RM; Deutch AY; Zald DH; Claassen DO
Neuroimage Clin; 2018; 18():433-442. PubMed ID: 29541577
[TBL] [Abstract][Full Text] [Related]
28. The catechol-O-methyltransferase Val(158)Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinson's disease: a PET study.
Wu K; O'Keeffe D; Politis M; O'Keeffe GC; Robbins TW; Bose SK; Brooks DJ; Piccini P; Barker RA
Brain; 2012 Aug; 135(Pt 8):2449-57. PubMed ID: 22843413
[TBL] [Abstract][Full Text] [Related]
29. Frontal, midbrain and striatal dopaminergic function in early and advanced Parkinson's disease A 3D [(18)F]dopa-PET study.
Rakshi JS; Uema T; Ito K; Bailey DL; Morrish PK; Ashburner J; Dagher A; Jenkins IH; Friston KJ; Brooks DJ
Brain; 1999 Sep; 122 ( Pt 9)():1637-50. PubMed ID: 10468504
[TBL] [Abstract][Full Text] [Related]
30. The dopaminergic basis of cognitive and motor performance in Alzheimer's disease.
Reeves S; Mehta M; Howard R; Grasby P; Brown R
Neurobiol Dis; 2010 Feb; 37(2):477-82. PubMed ID: 19914378
[TBL] [Abstract][Full Text] [Related]
31. Cognitive executive impairment and dopaminergic deficits in de novo Parkinson's disease.
Siepel FJ; Brønnick KS; Booij J; Ravina BM; Lebedev AV; Pereira JB; Grüner R; Aarsland D
Mov Disord; 2014 Dec; 29(14):1802-8. PubMed ID: 25284687
[TBL] [Abstract][Full Text] [Related]
32. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: a comparative PET study with [11C] raclopride and [11C]N-methylspiperone.
Kaasinen V; Ruottinen HM; Någren K; Lehikoinen P; Oikonen V; Rinne JO
J Nucl Med; 2000 Jan; 41(1):65-70. PubMed ID: 10647606
[TBL] [Abstract][Full Text] [Related]
33. Decreased binding of the D3 dopamine receptor-preferring ligand [11C]-(+)-PHNO in drug-naive Parkinson's disease.
Boileau I; Guttman M; Rusjan P; Adams JR; Houle S; Tong J; Hornykiewicz O; Furukawa Y; Wilson AA; Kapur S; Kish SJ
Brain; 2009 May; 132(Pt 5):1366-75. PubMed ID: 19153147
[TBL] [Abstract][Full Text] [Related]
34. Reduced striatal dopamine release during motor skill acquisition in Parkinson's disease.
Kawashima S; Ueki Y; Kato T; Ito K; Matsukawa N
PLoS One; 2018; 13(5):e0196661. PubMed ID: 29847548
[TBL] [Abstract][Full Text] [Related]
35. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography.
Brooks DJ; Ibanez V; Sawle GV; Playford ED; Quinn N; Mathias CJ; Lees AJ; Marsden CD; Bannister R; Frackowiak RS
Ann Neurol; 1992 Feb; 31(2):184-92. PubMed ID: 1575457
[TBL] [Abstract][Full Text] [Related]
36. Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism.
Scherfler C; Khan NL; Pavese N; Eunson L; Graham E; Lees AJ; Quinn NP; Wood NW; Brooks DJ; Piccini PP
Brain; 2004 Jun; 127(Pt 6):1332-42. PubMed ID: 15090472
[TBL] [Abstract][Full Text] [Related]
37. Apathy and striatal dopamine defects in non-demented patients with Parkinson's disease.
Chung SJ; Lee JJ; Ham JH; Lee PH; Sohn YH
Parkinsonism Relat Disord; 2016 Feb; 23():62-5. PubMed ID: 26717857
[TBL] [Abstract][Full Text] [Related]
38. Hyperstimulation of striatal D2 receptors with sleep deprivation: Implications for cognitive impairment.
Volkow ND; Tomasi D; Wang GJ; Telang F; Fowler JS; Wang RL; Logan J; Wong C; Jayne M; Swanson JM
Neuroimage; 2009 May; 45(4):1232-40. PubMed ID: 19349237
[TBL] [Abstract][Full Text] [Related]
39. Oral methylphenidate fails to elicit significant changes in extracellular putaminal dopamine levels in Parkinson's disease patients: positron emission tomographic studies.
Koochesfahani KM; de la Fuente-Fernández R; Sossi V; Schulzer M; Yatham LN; Ruth TJ; Blinder S; Stoessl AJ
Mov Disord; 2006 Jul; 21(7):970-5. PubMed ID: 16570297
[TBL] [Abstract][Full Text] [Related]
40. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
